<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882956</url>
  </required_header>
  <id_info>
    <org_study_id>Hamaky11</org_study_id>
    <nct_id>NCT04882956</nct_id>
  </id_info>
  <brief_title>BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration</brief_title>
  <official_title>Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-Related macular neovascularization degeneration occur is a vision threatening condition.&#xD;
      The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the&#xD;
      management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done.&#xD;
      Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech,&#xD;
      South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in BCVA in LOG MARS(logarithm minimum angle of resolution</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Macula Lutea Degeneration</condition>
  <arm_group>
    <arm_group_label>BEOVU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection</intervention_name>
    <description>Brolucizumab-Dbll intravitreal injection</description>
    <arm_group_label>BEOVU</arm_group_label>
    <other_name>BEOVU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection</intervention_name>
    <description>Aflipercept intravitreal injection</description>
    <arm_group_label>Eylea</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Age-Related macular neovascularization degeneration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other causes of macular neovascularization degeneration&#xD;
&#xD;
          -  other macular diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Elhamaky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha Faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarek R Elhamaky, MD</last_name>
    <phone>+97126324200</phone>
    <email>thamaky@ibnnafees.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarek Elhamaky, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INMC</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>46266</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAREK R ELHAMAKY, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Tarek Roshdy mohamed Mahgoub ELhamaky</investigator_full_name>
    <investigator_title>Professor (associate)</investigator_title>
  </responsible_party>
  <keyword>macular degeneration</keyword>
  <keyword>BEOVU</keyword>
  <keyword>Eylea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>by direct contact through email</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>unlimited</ipd_time_frame>
    <ipd_access_criteria>direct request by email</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

